Skip to main content
Year archive

Novo Nordisk — 2020 filings

All 244 regulatory filings released by Novo Nordisk (NOVO) in 2020, sourced directly from the official regulator.

244 Filings
2020 Period
2020 filings (244)
Filing Released Lang
FORM 6-K
Regulatory Filings
2020-12-29 English
Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Regulatory Filings
2020-12-29 English
Regulatory Filings 2020
Regulatory Filings
2020-12-29 English
FORM 6-K
Regulatory Filings
2020-12-22 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-12-22 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-12-22 English
FORM 6-K
Regulatory Filings
2020-12-18 English
Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management
Report Publication Announcement
2020-12-18 English
Regulatory Filings 2020
Regulatory Filings
2020-12-18 English
FORM 6-K
Regulatory Filings
2020-12-16 English
Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide
Regulatory Filings
2020-12-16 English
Regulatory Filings 2020
Regulatory Filings
2020-12-16 English
FORM 6-K
Regulatory Filings
2020-12-14 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-12-14 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-12-14 English
FORM 6-K
Regulatory Filings
2020-12-07 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-12-07 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-12-07 English
FORM 6-K
Regulatory Filings
2020-12-04 English
Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management
Regulatory Filings
2020-12-04 English
Regulatory Filings 2020
Regulatory Filings
2020-12-04 English
FORM 6-K
Regulatory Filings
2020-11-30 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-11-30 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-11-30 English
FORM 6-K
Regulatory Filings
2020-11-24 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-11-23 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-11-23 English
FORM 6-K
Regulatory Filings
2020-11-18 English
Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial
Regulatory Filings
2020-11-17 English
Regulatory Filings 2020
Regulatory Filings
2020-11-17 English
FORM 6-K
Regulatory Filings
2020-11-17 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-11-16 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-11-16 English
FORM 6-K
Regulatory Filings
2020-11-09 English
FORM 6-K
Regulatory Filings
2020-11-09 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-11-09 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-11-09 English
Trading in Novo Nordisk shares by board members, executives and associated persons on 4 and 5 November 2020
Director's Dealing
2020-11-06 English
Director's Dealing 2020
Director's Dealing
2020-11-06 English
FORM 6-K
Regulatory Filings
2020-11-05 English
Trading in Novo Nordisk shares by board members, executives and associated persons on 4 November 2020
Director's Dealing
2020-11-05 English
Director's Dealing 2020
Director's Dealing
2020-11-05 English
FORM 6-K
Regulatory Filings
2020-11-04 English
FORM 6-K
Regulatory Filings
2020-11-04 English
FORM 6-K
Regulatory Filings
2020-11-04 English
Trading in Novo Nordisk shares by board members, executives and associated persons on 3 November 2020
Director's Dealing
2020-11-03 English
Director's Dealing 2020
Director's Dealing
2020-11-03 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-11-03 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-11-03 English
Novo Nordisk A/S purchases B shares worth DKK 2,913 million from Novo Holdings A/S under the 2020 share repurchase programme
Transaction in Own Shares
2020-11-03 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-11-03 English
6-K
Regulatory Filings
2020-10-30 English
FORM 6-K
Regulatory Filings
2020-10-29 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-10-29 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-10-29 English
FORM 6-K
Regulatory Filings
2020-10-26 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-10-26 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-10-26 English
FORM 6-K
Regulatory Filings
2020-10-19 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-10-19 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-10-19 English
FORM 6-K
Regulatory Filings
2020-10-14 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-10-12 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-10-12 English
FORM 6-K
Regulatory Filings
2020-10-08 English
Novo Nordisk raises sales and operating profit outlook for 2020
Earnings Release 9M 2020
2020-10-08 English
Earnings Release 2020
Earnings Release 9M 2020
2020-10-08 English
FORM 6-K
Regulatory Filings
2020-10-05 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-10-05 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-10-05 English
FORM 6-K
Regulatory Filings
2020-09-28 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-09-28 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-09-28 English
FORM 6-K
Regulatory Filings
2020-09-22 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-09-21 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-09-21 English
FORM 6-K
Regulatory Filings
2020-09-14 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-09-14 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-09-14 English
FORM 6-K
Regulatory Filings
2020-09-08 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-09-07 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-09-07 English
FORM 6-K
Regulatory Filings
2020-08-31 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-08-31 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-08-31 English
FORM 6-K
Regulatory Filings
2020-08-24 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-08-24 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-08-24 English
FORM 6-K
Regulatory Filings
2020-08-17 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-08-17 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-08-17 English
6-K
Regulatory Filings
2020-08-06 English
FORM 6-K
Regulatory Filings
2020-08-06 English
Novo Nordisk's operating profit increased by 9% in Danish kroner and by 8% at constant exchange rates (CER) in the first six months of 2020
Earnings Release H1 2020
2020-08-06 English
Interim / Quarterly Report 2020
Interim / Quarterly Report H1 2020
2020-08-06 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-08-05 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-08-05 English
FORM 6-K
Regulatory Filings
2020-07-28 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-07-28 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-07-28 English
FORM 6-K
Regulatory Filings
2020-07-20 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-07-20 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-07-20 English
FORM 6-K
Regulatory Filings
2020-07-13 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-07-13 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-07-13 English
FORM 6-K
Regulatory Filings
2020-07-06 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-07-06 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-07-06 English
FORM 6-K
Regulatory Filings
2020-06-29 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-06-29 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-06-29 English
FORM 6-K
Regulatory Filings
2020-06-29 English
Rybelsus® approved in Japan for the treatment of type 2 diabetes
Regulatory Filings
2020-06-29 English
Regulatory Filings 2020
Regulatory Filings
2020-06-29 English
Regulatory Filings 2020
Regulatory Filings
2020-06-25 English
Regulatory Filings 2020
Regulatory Filings
2020-06-25 English
FORM 6-K
Regulatory Filings
2020-06-22 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-06-22 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-06-22 English
FORM 6-K
Regulatory Filings
2020-06-18 English
Regulatory Filings 2020
Regulatory Filings
2020-06-18 English
Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity
Regulatory Filings
2020-06-18 English
FORM 6-K
Regulatory Filings
2020-06-15 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-06-15 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-06-15 English
FORM 6-K
Regulatory Filings
2020-06-12 English
Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the programme
Regulatory Filings
2020-06-12 English
Environmental & Social Information 2020
Environmental & Social Information
2020-06-12 English
FORM 6-K
Regulatory Filings
2020-06-05 English
Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial
Regulatory Filings
2020-06-04 English
Earnings Release 2020
Earnings Release FY 2020
2020-06-04 English
FORM 6-K
Regulatory Filings
2020-06-03 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-06-03 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-06-03 English
FORM SD
Regulatory Filings
2020-05-28 English
FORM 6-K
Regulatory Filings
2020-05-26 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-05-25 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-05-25 English
FORM 6-K
Regulatory Filings
2020-05-13 English
Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial
Regulatory Filings
2020-05-13 English
Earnings Release 2020
Earnings Release FY 2020
2020-05-13 English
FORM 6-K
Regulatory Filings
2020-05-12 English
Trading in Novo Nordisk shares by board members, executives and associated persons on 11 May 2020
Director's Dealing
2020-05-12 English
Director's Dealing 2020
Director's Dealing
2020-05-12 English
FORM 6-K
Regulatory Filings
2020-05-12 English
FORM 6-K
Regulatory Filings
2020-05-12 English
FORM 6-K
Regulatory Filings
2020-05-12 English
Novo Nordisk A/S:
Director's Dealing
2020-05-11 English
Director's Dealing 2020
Director's Dealing
2020-05-11 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-05-11 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-05-11 English
Novo Nordisk A/S purchases B shares worth DKK 3,051 million from Novo Holdings A/S under the 2020 share repurchase programme
Transaction in Own Shares
2020-05-11 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-05-11 English
FORM 6-K
Regulatory Filings
2020-05-11 English
Trading in Novo Nordisk shares by board members, executives and associated persons on 7 May 2020
Director's Dealing
2020-05-11 English
Director's Dealing 2020
Director's Dealing
2020-05-11 English
6-K
Regulatory Filings
2020-05-06 English
FORM 6-K
Regulatory Filings
2020-05-05 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-05-05 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-05-05 English
FORM 6-K
Regulatory Filings
2020-04-30 English
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2020
Regulatory Filings
2020-04-30 English
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2020
Share Issue/Capital Change
2020-04-30 English
FORM 6-K
Regulatory Filings
2020-04-30 English
FORM 6-K
Regulatory Filings
2020-04-30 English
Novo Nordisk A/S – Reduction of the share capital
Share Issue/Capital Change
2020-04-28 English
Novo Nordisk A/S – Reduction of the share capital
Share Issue/Capital Change
2020-04-28 English
FORM 6-K
Regulatory Filings
2020-04-28 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-04-27 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-04-27 English
FORM 6-K
Regulatory Filings
2020-04-20 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-04-20 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-04-20 English
FORM 6-K
Regulatory Filings
2020-04-06 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-04-06 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-04-06 English
FORM 6-K
Regulatory Filings
2020-04-06 English
Regulatory Filings 2020
Regulatory Filings
2020-04-04 English
Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU
Regulatory Filings
2020-04-04 English
FORM 6-K
Regulatory Filings
2020-03-31 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-03-31 English
Novo Nordisk A/S - Share repurchase programme
Transaction in Own Shares
2020-03-31 English
Novo Nordisk A/S - Share repurchase programme
Transaction in Own Shares
2020-03-31 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-03-31 English
FORM 6-K
Regulatory Filings
2020-03-27 English
FORM 6-K
Regulatory Filings
2020-03-26 English
FORM 6-K
Regulatory Filings
2020-03-23 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-03-23 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-03-23 English
FORM 6-K
Regulatory Filings
2020-03-17 English
FORM 6-K
Regulatory Filings
2020-03-17 English
Novo Nordisk pauses the clinical trials investigating concizumab (anti-TFPI mAB) in haemophilia A and B with or without inhibitors
Regulatory Filings
2020-03-16 English
Regulatory Filings 2020
Regulatory Filings
2020-03-16 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-03-16 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-03-16 English
FORM 6-K
Regulatory Filings
2020-03-09 English
Novo Nordisk A/S: Share repurchase programme
Transaction in Own Shares
2020-03-09 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-03-09 English
FORM 6-K
Regulatory Filings
2020-03-03 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-03-02 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-03-02 English
FORM 6-K
Regulatory Filings
2020-02-28 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-02-24 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-02-24 English
FORM 6-K
Regulatory Filings
2020-02-21 English
FORM 6-K
Regulatory Filings
2020-02-14 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-02-14 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-02-14 English
FORM 6-K
Regulatory Filings
2020-02-14 English
Trading in Novo Nordisk shares by board members, executives and associated persons on 11 February 2020
Director's Dealing
2020-02-14 English
Director's Dealing 2020
Director's Dealing
2020-02-14 English
FORM 6-K
Regulatory Filings
2020-02-11 English
FORM 6-K
Regulatory Filings
2020-02-11 English
Trading in Novo Nordisk shares by board members, executives and associated persons on 7 February 2020
Director's Dealing
2020-02-11 English
Director's Dealing 2020
Director's Dealing
2020-02-11 English
Trading in Novo Nordisk shares by board members, executives and associated persons on 5 - 8 February 2020
Director's Dealing
2020-02-10 English
Director's Dealing 2020
Director's Dealing
2020-02-10 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-05 English
6-K
Regulatory Filings
2020-02-05 English
IRANNOTICE
Regulatory Filings
2020-02-05 English
20-F
Annual Report FY 2019
2020-02-05 English
6-K
Regulatory Filings
2020-02-05 English
Novo Nordisk's operating profit increased by 11% in Danish kroner and by 6% at constant exchange rates (CER) in 2019
Earnings Release FY 2019
2020-02-05 English
Earnings Release 2019
Earnings Release FY 2019
2020-02-05 English
FORM 6-K
Regulatory Filings
2020-02-04 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-02-04 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-02-04 English
FORM SC 13G
Major Shareholding Notification
2020-02-03 English
FORM 6-K
Regulatory Filings
2020-01-31 English
Rybelsus® (oral semaglutide) recommended for approval for the treatment of adults with type 2 diabetes by the European regulatory authorities
Regulatory Filings
2020-01-31 English
Regulatory Filings 2020
Regulatory Filings
2020-01-31 English
FORM 6-K
Regulatory Filings
2020-01-27 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-01-27 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-01-27 English
FORM 6-K
Regulatory Filings
2020-01-21 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-01-20 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-01-20 English
FORM 6-K
Regulatory Filings
2020-01-17 English
Ozempic® approved in the US for CV risk reduction in people with type 2 diabetes and established CVD
Regulatory Filings
2020-01-16 English
Regulatory Filings 2020
Regulatory Filings
2020-01-16 English
FORM 6-K
Regulatory Filings
2020-01-13 English
Novo Nordisk A/S – Share repurchase programme
Transaction in Own Shares
2020-01-13 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-01-13 English